According to the latest global cancer burden data released by the World Health Organization (WHO) International Agency for Research on Cancer (IARC) in 2020, breast cancer replaced lung cancer with 2.26 million new cases to become the world's largest cancer. According to the "Chinese Female Breast Cancer Screening Standards" issued by the National Cancer Center in 2021, ultrasound is currently the preferred breast cancer screening method in China.
Top grade has created the first domestic automatic breast volume ultrasound device for Shenbo Medical, and in 2019 obtained the registration certificate of innovative medical device products issued by the Drug Administration. In the same year, Shenbo Medical successfully completed the C round of financing, in 2020, the domestic private medical examination industry leading enterprises Meinian Health introduced the Shenbo Medical's automatic breast volume ultrasound.
Meinian Health is committed to providing high-quality physical examination services and bringing the most advanced physical examination experience to the subjects. For more than a year, Shenbo Medical's automatic breast volume ultrasound has been applied to physical examination centers in more than 20 cities across the country. The cumulative number of examinations has reached thousands of cases, with positive detection rates (including nodules, masses, etc.) approaching 70% and major positive detection rates approaching 3%. In addition to relying on the cooperation with the United States to accelerate the layout of urban areas, Shenbo Medical is to the pain point is more obvious, the demand for greater rural grass-roots breast cancer screening market.
The goal of Shenbo Medical is to use breast volume ultrasound technology and AI-assisted diagnosis system to form an innovative solution for intelligent early screening of breast cancer, to improve the early diagnosis rate of breast cancer, to sink breast cancer screening services to the grass-roots level, to promote the popularization of breast cancer screening to rural areas, to help improve the screening coverage rate and early diagnosis rate in rural grass-roots areas, to reduce the occurrence of poverty due to disease, and to achieve common prosperity.
According to Shenbo Medical, its AI-assisted diagnostic system has entered the multi-center clinical trial stage and will receive NMPA three-class certificate in the near future. At that time, Shenbo Medical will formally form a complete solution to realize the standardization, automation and intelligence of breast cancer screening and diagnosis, and truly meet the needs of large-scale group screening.